Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05462353
Other study ID # ASC41-202
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date September 30, 2022
Est. completion date June 10, 2025

Study information

Verified date April 2024
Source Gannex Pharma Co., Ltd.
Contact Junping Shi, Doctor
Phone 13957121199
Email 13957121199@vip.126.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a Phase 2, Double-Blind, Randomized, Multicenter, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Efficacy of ASC41 in Adults with Nonalcoholic Steatohepatitis (NASH).


Recruitment information / eligibility

Status Recruiting
Enrollment 180
Est. completion date June 10, 2025
Est. primary completion date May 10, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: - Age = 18 and = 80 years old at screening. - Presence of = 7.5% steatosis on screening MRI-PDFF read centrally by a radiologist and performed either during the screening period or within 6 months prior to the first visit. - HbA1c = 9.5%. - Normal or minimally abnormal renal function as defined by estimated glomerular filtration rate (eGFR) = 50 mL/min/1.73 m^2 Exclusion Criteria: - Presence or history of cirrhosis or evidence of decompensated liver disease (e.g., ascites, variceal bleeding) or hepatocellular carcinoma. - History or presence of other concomitant liver disease as assessed by the investigator or determined by laboratory findings. - Uncontrolled Type 2 diabetes mellitus (T2DM) defined as HbA1c of > 9.5% within 60 days prior to enrollment. - Change in anti-diabetic therapy within 6 months prior to qualifying liver biopsy.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
2mg of ASC41
ASC41 tablet administered orally once daily.
4mg of ASC41 (2 tablets of 2 mg ASC41)
ASC41 tablets administered orally once daily.
Placebo
Placebo tablets administered orally once daily.

Locations

Country Name City State
China The affiliated Hospital of Hangzhou Normal University Hangzhou Zhejiang

Sponsors (1)

Lead Sponsor Collaborator
Gannex Pharma Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary To evaluate the effect of ASC41 compared with placebo in noncirrhotic subjects with NASH by a histological change. A histological change in NAFLD (nonalcoholic fatty liver disease) Activity Score (NAS) = 2 points that results from reduction of necroinflammation (inflammation or ballooning) without worsening fibrosis. (The NAFLD Activity Score including steatosis, inflammation and ballooning. The maximum score of steatosis was 3 and the minimum score was 0, the maximum score of inflammation was 3 and the minimum score was 0, and the maximum score of ballooning was 2 and the minimum score was 0. The higher scores mean a worse outcome. ) Baseline and Week 52
Secondary The incidence, type and severity of AEs/SAEs were assessed by CTCAE v5.0 to assess the safety and tolerability of ASC41 compared to placebo 24 and 52 weeks
Secondary Change from baseline in hepatic fat fraction assessed by MRI-PDFF 24 and 52 weeks
Secondary To evaluate the effect of ASC41 compared with placebo on serum lipids (cholesterol, HDL-C, LDL-C, triglycerides, Lp(a), VLDL) 12, 24 and 52 weeks
Secondary Plasma pharmacokinetics - Peak Plasma Concentration (Cmax) Measured after administration 1 and 15 Days
Secondary Plasma pharmacokinetics - Area under the plasma drug concentration versus time curve( AUC0-t_, AUC0-8) 1 and 15 Days
Secondary Plasma pharmacokinetics - The amount of time that a drug is present at the maximum concentration in serum(Tmax) 1 and 15 Days
See also
  Status Clinical Trial Phase
Recruiting NCT05480696 - Soluble Fibre Supplementation in NAFLD Phase 1
Active, not recruiting NCT02500147 - Metformin for Ectopic Fat Deposition and Metabolic Markers in Polycystic Ovary Syndrome (PCOS) Phase 4
Completed NCT04671186 - Role of Probiotics in Treatment of Pediatric NAFLD Patients by Assessing With Fibroscan N/A
Recruiting NCT05979779 - Ph 2 Study of the Safety and Efficacy of Three HU6 Dose Levels and Placebo in Nonalcoholic Steatohepatitis Phase 2
Completed NCT05006885 - ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With Non-alcoholic Fatty Liver Disease (NAFLD) Phase 1
Completed NCT04117802 - Effects of Maple Syrup on Gut Microbiota Diversity and Metabolic Syndrome N/A
Recruiting NCT04365855 - The Olmsted NAFLD Epidemiology Study (TONES) N/A
Recruiting NCT05618626 - Prevention of NAFLD and CVD Through Lifestyle Intervention N/A
Completed NCT03256526 - 6-week Safety and PD Study in Adults With NAFLD Phase 2
Enrolling by invitation NCT06152991 - Clinical Trial Assessing Godex Carnitine Orotate Complex in Nonalcoholic Fatty Liver Disease Patients for Efficacy Phase 3
Completed NCT03681457 - Evaluation of the Pharmacokinetics of Tropifexor in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared to Healthy Control Subjects Phase 1
Completed NCT06244550 - Clinical Trials Using HepatoKeeper Herbal Essentials to Treat Non-alcoholic Fatty Liver Disease and Metabolic Factors N/A
Not yet recruiting NCT05120557 - Point-of-care Ultrasound Screening and Assessment of Chronic Liver Diseases and NASH N/A
Completed NCT03060694 - Screening Diabetes Patients for NAFLD With Controlled Attenuation Parameter and Liver Stiffness Measurements
Completed NCT02526732 - Hepatic Inflammation and Physical Performance in Patients With NASH N/A
Recruiting NCT01988441 - The Influence of Autophagy on Fatty Liver
Recruiting NCT01680003 - Hepar-P Study to Evaluate the Safety and Efficacy of a Standardised Extract of Phyllanthus Niruri for the Treatment of Non-alcoholic Fatty Liver Disease Phase 2
Completed NCT01712711 - Helicobacter Pylori Eradication in Diabetic Subjects With Non-alcoholic Fatty Liver Disease Phase 2
Recruiting NCT00941642 - Placebo Controlled Study Using Lovaza as Treatment for Non-Alcoholic Fatty Liver Disease Phase 4
Completed NCT01257685 - Selenoprotein P and Non-alcoholic Fatty Liver Disease